Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and biopharmaceutical manufacturing. Cell therapy is one of the fastest-growing areas of the life sciences. It entails delivering entire living cells to a patient to treat chronic and rare disorders. Despite being a niche domain of the biotechnology sector, cell and gene therapy have paved the investments by the contract development and manufacturing organizations (CDMO)/contract manufacturing organizations (CMO).
It involves the delivery of whole, living cells to a patient for the treatment of the disease. Typically, this category is divided into two main sections—autologous, meaning the cells are derived from the patient, and allogenic, meaning the cells are derived from another individual and show some match to the potential new host, similar to a blood transfusion.
COVID-19 Impact analysis
- The COVID-19 outbreak is predicted to have a minor or insignificant influence on the market for cell therapy technology. There is a greater need for an effective COVID-19 medicine or vaccination that could help to reduce the severity of the diseases with the growth of COVID-19 instances. Cell-based research is an important step in the production of vaccines, and help boost the growth of the market. The supply chain was disrupted during the early months of the COVID-19 outbreak, which caused the clinical studies to be delayed. This may have a negative impact on the market to some extent. Clinical trial delays have been revealed by biopharmaceutical companies, including significant players such as Pfizer and Eli Lilly.
Top Impacting Factors
The cell therapy biomanufacturing market is predicted to grow due to a greater focus on personalized medicine and increase in public-private partnerships for the development of cell treatments.
An increase in the frequency of cardiovascular illnesses, a rise in the demand for chimeric antigen receptor (CAR) T cell therapy, and the continued development of stem cell therapy methods are the factors propelling the cell therapy biomanufacturing market growth.
Customers and other stakeholders are collaborating with biomanufacturing companies to improve the clinical research and commercial manufacturing of these medicines. This in turn is expected to boost the growth of the cell therapy biomanufacturing market.
Manufacturers' bottlenecks during cell therapy commercialization, high costs involved with cell therapies, and absence of a qualified personnel to run complicated instruments limit the cell therapy biomanufacturing market growth.
Market Trends
New product launches to flourish the market
- In November 2019, the Australian government released a 10-year roadmap for stem cell research in Australia—The Stem Cell Therapies Mission. The initiative is anticipated to provide USD 102 million (AU$150 million) under the Medical Research Future Fund (MRFF) to support stem cell research to deliver new therapies.
- In 2020, Lonza (Switzerland) collaborated with IsoPlexis (U.S.) to develop the next generation of precision cell therapy manufacturing.
- In 2020, Biopharma business from General Electric Company’s Life Sciences division (U.S.) Danaher acquired the Biopharma business from General Electric Company’s Life Sciences division. The acquisition led to a new business named Cytiva, a standalone operating company within Danaher’s Life Sciences segment.
- In 2019, Thermo Fisher Scientific invested ~USD 24 million in its Inchinnan (Scotland) site to expand its global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell culture media.
Key Benefits of the Report
- This study presents the analytical depiction of the Cell Therapy Biomanufacturing along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Cell Therapy Biomanufacturing market share.
- The current market is quantitatively analyzed to highlight the Cell Therapy Biomanufacturing market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed Cell Therapy Biomanufacturing market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Cell Therapy Biomanufacturing Report
- Who are the leading market players active in the Cell Therapy Biomanufacturing market?
- What current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What future projections would help in taking further strategic steps?
- What is "Cell Therapy Biomanufacturing "?
- What is "Cell Therapy Biomanufacturing " Market prediction in the future?
- Who are the leading global players in the "Cell Therapy Biomanufacturing " Market?
- What are the current trends and predicted trends?
- What are the key benefits of the "Cell Therapy Biomanufacturing " Market report?
Cell Therapy Biomanufacturing Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Cell Type |
|
 By Process |
|
 By End User |
|
 By Region |
|
 Key Market Players | Hemasoft (US), MaxCyte (US), Fresenius Medical Care AG & Co. KGaA (Germany), Lonza Group (Switzerland, STEMCELL Technologies (Canada), L7 Informatics, Inc. (US), Terumo BCT (US), SIRION Biotech GmbH (Germany), RoosterBio Inc. (US), Sartorius AG (Germany), IxCells Biotechnology (China), CellGenix GmbH (Germany), Dickinson and Company (US), Corning Incorporated (US), Miltenyi Biotec GmbH (Germany), Becton, Wilson Wolf Corporation (US)., OrganaBio, LLC (US), Werum IT Solutions GmbH (Germany), Bio-Techne Corporation (US), Avantor, Inc. (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), FUJIFILM Irvine Scientific (US), Merck KGaA (Germany). MaxCyte (US), MAK-SYSTEM (US) |
Loading Table Of Content...
